The ranked assignee list is heavily top-weighted: a single leading assignee holds 1,614 of the 3,535 records in scope, and the top five together account for 78.9% of all records. Fifth place holds 169 records and tenth place 65, showing a steep drop after the leaders rather than a gradual taper. Several of the largest holders are linked through shared named inventors on early foundational patents, which later consolidated into corporate portfolios, so counting by company alone can understate how concentrated the underlying research lineage actually is.

Filing volume peaked in 2019 at 207 records and has since settled into a plateau: complete-year data shows 82 filings in 2021 against 83 in 2024, a span of just +1%. That is neither strong growth nor a decline, but a mature, steady-state filing rate. Figures for 2025 and 2026 appear lower in the raw count, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity, so those years should not be read as a downturn.

C12N, covering microorganisms and genetic engineering, appears on 70.5% of the 3,535 records in scope, and A61K, medicinal preparations, on 63.0%. C07K, peptides and proteins, is close behind at 62.8%. These three classes together indicate the field is anchored in cell and molecular engineering claims rather than device engineering alone, even though mechanoporation devices are a growing recent theme. Measurement and testing-oriented classes such as C12Q, G01N and C07H each cover under a third of records, marking comparatively lighter claim density there.

The clearest gaps sit in classes with lower record coverage relative to the core engineering classes: C07H (sugars and nucleic acids) covers only 14.0% of records, and C12Q and G01N, both measurement- and testing-related, sit at 32.1% and 24.6% respectively. Combined with the plateaued overall filing rate, this suggests analytical methods tied to editing efficiency, viability measurement and closed-system reagent control are less crowded than the underlying delivery mechanism claims themselves. A first claim in this space would likely pair a specific measurement method with a defined nonviral delivery step rather than claim the delivery mechanism broadly.

US20260234534A1, filed by Portal Biotechnologies, claims a disposable tubing set for membrane mechanoporation designed to work with existing pumps and cell-processing equipment at lower operating pressures. It sits within the closed-system processing segment of the field rather than electrical electroporation, so it is most relevant to companies building disposable or single-use mechanoporation workflows rather than those using established electrical transfection methods. Anyone designing a similar tubing-based perturbation filter or cell-suspension mixing approach should review this filing's specific claim scope before finalising a device architecture.